Previous close | 8.04 |
Open | 7.99 |
Bid | 7.62 x 300 |
Ask | 7.65 x 200 |
Day's range | 7.61 - 8.00 |
52-week range | 7.61 - 27.48 |
Volume | |
Avg. volume | 1,054,298 |
Market cap | 1.036B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vir Biotechnology Inc (NASDAQ:VIR), a company focused on the research and development of treatments for serious infectious diseases, has reported an insider sell according to a recent SEC filing.
Q4 2023 Vir Biotechnology Inc Earnings Call